Proposed 2027 MHBP Standard Plan Signals Higher GLP-1 Member Costs

Discussion of the proposed 2027 MHBP Standard Plan describes a substantial change in member cost sharing for GLP-1 medications. The reported comparison is 30% coinsurance capped at $200 in 2026 versus 50% coinsurance with no stated cap in 2027. The discussion does not establish the finalized plan terms, the applicable plan allowance, or which GLP-1 drugs will qualify. Federal benefits teams and contractors supporting plan administration should therefore treat the change as a signal to verify—not as a confirmed coverage determination.

One commenter illustrated the potential impact using a reported $1,000 monthly drug cost: “So I read it as 50% of the plan allowance. My most recent EOB shows that the drug cost was $1,000 for a one-month supply, with my share being $200 and the plan’s share being $800 ... my share will now be $500, before any manufacturer’s coupon.” That example suggests a possible increase from $200 to $500, but it is not a confirmed estimate for all enrollees. Actual member responsibility may depend on the plan’s negotiated or otherwise applicable allowance, final cost-sharing provisions, drug eligibility, and any discounts or coupons.

For stakeholders in the Federal Employees Health Benefits Program (FEHB), the immediate procurement and administration implication is a need to monitor finalized benefit documents and prepare for member questions. The discussion references the Office of Personnel Management (OPM) and claims that similar changes may be occurring in other plans or reflect an OPM-related change, but these claims are unconfirmed in the source. Nothing in the discussion confirms a new OPM-wide policy, a solicitation, or a contract award. Plan sponsors, benefits consultants, pharmacy benefit administrators, and help desks should distinguish reported proposals from approved plan terms.

The reported shift may affect affordability conversations and utilization patterns involving GLP-1 coverage. Companies mentioned in the discussion—including Novo Nordisk, Eli Lilly, CVS Health / Aetna, Blue Cross Blue Shield (BCBS), and GEHA—may be relevant to member inquiries about manufacturers, insurers, and plan options, but the source does not establish that any of these organizations made or implemented the proposed change. Alternatives raised in the discussion, such as manufacturer discounts, high-deductible health plans (HDHPs), and cash-pay or compounded medications, carry different coverage, pricing, and regulatory considerations and should not be treated as interchangeable benefits.

• The proposed 2027 MHBP Standard Plan is described as moving GLP-1 cost sharing from 30% coinsurance capped at $200 in 2026 to 50% coinsurance with no stated cap.
• The final 2027 terms are unclear; verify the coinsurance cap, plan allowance, and eligible GLP-1 drugs in finalized plan materials.
• The cited example estimates a member share rising from $200 to $500 on a reported $1,000 monthly drug cost, before any manufacturer coupon; it is illustrative, not a confirmed universal cost.
• Benefits teams and plan administrators should confirm terms directly with the plan and OPM before communicating coverage or cost expectations to members.
• Claims that other plans have similar changes or that an OPM-related change is involved remain unconfirmed in the discussion.
• The signal concerns potential benefit design and member affordability; it is not evidence of a confirmed federal procurement action or government-wide policy change.
• Insurers, pharmacy benefit administrators, and manufacturers may face increased questions about coverage, eligibility, and out-of-pocket costs.
• Manufacturer discounts, HDHPs, cash-pay options, and compounded medications have distinct coverage, cost, and regulatory considerations.